Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 2Phase 4 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 15Plasma cell 10Breast 6Lymphoid 3Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × liposomal doxorubicin × Genitourinary × Clear all
NCT00456989 2019-10-30

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

University of Louisville

Phase 1/2 Completed
39 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

NCT00132756 2006-11-08

Liposomal Doxorubicin and Estramustine Phosphate: Study in Taxane Resistant, Hormone Refractory Advanced Prostate Cancer

Morton Plant Mease Health Care

Phase 1/2 Terminated
30 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡